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ABSTRACT 
Free radical damage has been associated with atherosclerosis, age-
related macular degeneration, and age-related cataracts. Free 
radicals cause damage to human tissues through oxidative stress. 
Protection against free radicals has been found with the use of 
antioxidants, such as vitamin C, vitamin E, and beta-carotene. 
Antioxidants neutralize the free radicals and prevent tissue damage; 
therefore antioxidants are increasingly becoming routine therapies 
for such diseases as atherosclerosis. Foods may contain other 
antioxidants such as bioflavonoids and carotenoids other than beta-
carotene. Research is showing how bioflavonoids and carotenoids 
inhibit lipid peroxidation and platelet aggregation and thus may be 
even more beneficial than current therapies for free radical damage. 
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Much interest has been shown recently about free radical 
production and free radical damage in the body. Free radical damage 
has been associated with coronary heart disease, age-related macular 
degeneration, cataracts, and cancer. Certain vitamins such as E and C 
are thought to act as antioxidants, protecting against free radical 
damage. It is also thought that foods may contain other substances 
that are protective against free radicals and are possibly even more 
powerful than the well known antioxidants. This paper will discuss 
bioflavonoids and carotenoids found in foods that may protect 
against free radical damage. 
FREE RADICALS 
Free radicals are molecules that have an unpaired electron in 
their outermost orbit, thereby making them highly reactive. Oxygen 
free radicals are common in the body as they are produced by many 
human metabolic processes (1). In an oxygen free radical, the 
oxygen molecule is left with an unpaired electron and wants to react 
with another substance to become more stable. If two radicals react, 
they bond sharing an electron and the free radicals are eliminated. 
If a free radical reacts with a nonradical, it pulls away an electron 
leaving the nonradical now a free radical. This can cause a chain 
reaction resulting in damaged molecules (2). 
Free radicals are produced within cells during many metabolic 
processes, as well as being produced by environmental changes and 
through foreign compounds. Foreign compounds that cause free 
radicals include carbon tetracholoride, which is used in dry cleaning 
and degreasing, and Adriamycin, an anti-cancer drug (3). The 
following are specialized mechanisms of free radical production 
which can create free radical damage in the body. 
Phagocytic cells, when active, create a "respiratory burst" 
which is composed of free radicals produced from the oxygen they 
consume. These free radicals are used to destroy any phagocytized 
material (3)(Figure A). 
Hydrogen peroxide (H2 0 2) in combination with metal ions can 
be converted to hydroxyl radicals (OH'), hydroxyl ions (OH-) and 
oxygen (02) (Reaction 1). Radicals are also formed by the Haber-
Weiss reaction which uses the metal ion as a catalyst rather than a 
substrate (Reaction 2)(1). 
Fe salt 
02·- + H202 --------> o2 + OH' + OH- (Reaction 2) 
Catalyst 
Since metal ions, such as iron and copper, can convert hydrogen 
peroxide to free radicals, the body keeps the metal ions bound to 
proteins as an antioxidant mechanism. This prevents free metal ions 
from aiding in production of free radicals or catalyzing free radical 
reactions ( 4 ). 
Much damage has been shown during ischemic reperfusion, 
possibly· in part due to free radicals. During ischemia, adenosine 
triphosphate (ATP) is catabolized to hypoxanthine. The enzyme, 
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Figure A. Free Radical Production and Damage 
Lipid Peroxidation 
xanthine dehydrogenase, is converted to xanthine oxidase by a 
protease. On reperfusion xanthine oxidase uses hypoxanthine as a 
substrate, producing free radicals (1). 
Ischemia also decreases superoxide dismutase (SOD), which is 
the enzyme produced in the body that helps catabolize superoxide 
anion radicals. One study on dogs having coronary artery occlusion 
showed that by administering superoxide dismutase at the time of 
reperfusion and continuing for 90 minutes, necrosis of the 
myocardial cells was decreased by 36% (1). By adding the enzyme 
that helps break down free radicals, less necrosis of the tissues 
resulted. This antioxidant mechanism may help in other areas of cell 
or tissue death. 
Another study has shown that animals having the longest 
lifespan showed higher levels of superoxide dismutase and a lower 
metabolic rate (1). 
FREE RADICAL DAMAGE 
Circulatory system 
Free radicals produced m the arterial endothelial and muscle 
cells (1) have been shown to damage vascular endothelium and to 
affect the regulators for vasculature permeability leading to 
atherosclerosis (3). Low density lipoproteins (LDLs) are blood lipids 
that are known to promote atherosclerosis. LDLs are deposited in the 
endothelial cells of the arterial wall. When free radicals oxidize LDLs, 
the LDLs in this altered state have different biological properties. 
The oxidized LDLs can easily be taken up by the macrophages, 
thereby leading to foam cell lesions within the arterial wall. These 
foam cell lesions can grow and eventually cause an atherosclerotic 
plaque (5,6). 
Another mechanism by which oxidized LDLs can contribute to 
atherosclerosis involves the endothelium derived relaxing factor 
(EDRF). The endothelial cells produce the relaxing factor (EDRF), 
which suppresses platelet activity and relaxes smooth muscle cells 
causing vasodilation (7). Studies have shown that "arteries exposed 
to oxidized LDL show an unresponsiveness to endothelium-derived 
vasodilators that is similar to that observed m atherosclerotic 
vessels" (6). Free radical damage to the endothelium destroys the 
ability of these cells to secrete the EDRF and this too can initiate 
atherosclerosis (7). Preventing oxidation, by quenching or 
neutralizing the free radicals, would protect the endothelial wall of 
the arterioles and decrease arteriosclerosis. 
Bleeding with lysed erythrocytes releases uon molecules that 
decompose H202 to free radicals (Figure A). Therefore, it has been 
shown that bleeding into the eye giving off unbound iron molecules 
can cause severe retinal degeneration from free radical damage (1). 
When the iron is bound to another molecule, such as protein, it is 
unable to participate m free radical production (4). 
Smoking and ARMD 
The Blue Mountains Eye Study conducted in Australia looked at 
the correlation between smoking and age-related macular 
degeneration in 3654 subjects. The results showed a significant 
association between current smokers and late ARMD as well as early 
ARMD. The subjects who had previously smoked during their life 
had an increased risk of late ARMD but not early ARMD (8). 
The Physicians Health Study subjects, 21,157 US male 
physicians, were assessed for their smoking habits and occurrence of 
ARMD. The ARMD was found to be dose dependent; therefore, those 
subjects who smoked the greatest number of packs per day were 
found to have a greater risk for developing ARMD. A 2-3 times 
increased risk for ARMD was shown for those who currently smoke 
or had smoked more than 1 pack per day (9). 
A similar study looked at women who smoked and their risk of 
developing ARMD. 31,843 registered nurses were followed over 12 
years. Those subjects that smoked 25 or more cigarettes per day 
were 2.4 times more likely to develop ARMD. Past smokers of this 
quantity of cigarettes were twice as likely to acquire ARMD as those 
who had never smoked (10). 
Current theories of how smoking mcreases the risk of ARMD 
include the production of free radicals in the retina caused by 
oxidants found in cigarette smoke and vascular changes in the 
choroid from lipid peroxidation resulting from free radical damage 
(9). Any substance found in foods that could neutralize free radicals 
then could decrease the risk of ARMD. 
Age-related Cataracts 
Age-related cataracts are formed due to lipid peroxidation 
from a photochemical reaction which generates superoxide anion 
radicals. The lens contains many oxygen free radical scavengers to 
prevent free radical injury, but if not enough free radical 
neutralizers are available for the amount of free radicals present, the 
damage occurs ( 1). 
Cigarette smoking 1s a risk factor for age-related cataracts. 
Smoking has been shown to increase the blood levels of products 
from lipid peroxidation caused by free radicals. A study published in 
the New England Journal of Medicine measured circulation levels of 
F2-isoprostanes, compounds produced by the peroxidation of 
arachidonic acid by free radicals, in smokers and non-smokers. The 
F2-isoprostane level of smokers was almost twice the level of non-
smokers (11). 
Another study investigated the incidence of cataracts in 
smokers using data from the Physicians' Health Study. It controlled 
other risk factors such as diabetes, alcohol use, blood pressure, 
physical activity and parental history of heart attacks through a 
questionnaire. A statistically significant increase in nuclear sclerosis 
and posterior subcapsular cataracts was found in current smokers 
who smoke 20 or more cigarettes per day. Past smokers showed an 
increase in posterior subcapsular cataracts (12). 
BIOFLA VONOIDS 
Bioflavonoids are a group of substances found naturally m foods 
giving flavor and color to many fruits, vegetables, wine and teas. 
The bioflavonoids are made up of phenolic compounds. The phenolic 
compounds act as antioxidants by donating an electron from their 
hydroxyl group and conjugated ring to a free radical, which then 
neutralizes or stabilizes the free radical (13); therefore, the more 
hydroxyl groups, the more effective the flavonoid Is as an 
antioxidant. 
All bioflavonoids contain the same basic chemical structure, C6-
C3-C6. Each flavonoid can be defined by its attached subgroup of 
sugars, hydroxyl, or methoxyl group(s) at various positions on the 
basic structure (14 ). 
The flavonoids can be divided into three major 
subcategories: catechols, anthocyanins, and anthoxanthins. Catechols 
and tannins, which are the brown pigments, are found in grains, 
barks, and peelings. Anthocyanins are the dark red, blue and purple 
pigments we find in fruits, vegetables, and flowers. These include 
cabbage, blueberries, grapes, and eggplants. Anthoxanthins have 
almost no pigment or a light yellow pigment. They are found in 
oranges, tangerines, grapefruits, lemons, carrots, zucchini, and yellow 
flowers (15). 
The plant bilberry, scientifically known as Vacciniium 
myrtillus, contains bilberry, an anthocyanoside and a powerful 
antioxidant, comparable to vitamin E (16). Studies have shown that 
after bilberry intake, night vision Improves as the rhodopsin 
chemical is recycled quicker and more effectively after light 
exposure (17). Most research on bilberry has been conducted m 
Europe. Doctors in Europe are prescribing bilberry with vitamin E to 
improve circulation and protect cell membranes (15). 
The anthoxanthins can be broken down into three subgroups: 
1. Flavanones - mainly found in citrus fruits and are a 
very pale yellow to colorless compound. 
2. Flavones - the dehydrogenated product of flavanones, 
thereby making it a more specialized flavonoid. These are found m 
flowers, seeds, leaves, and roots as pale yellow pigments. In the 
plants certain flavones act as ultraviolet sensors, and may also 
exhibit similar functions in humans (18). 
Quercetin, a flavone found in various plant rinds as well as m 
clover and ragweed(15), is one of the strongest antioxidants. 
Quercetin in tablet form is not recommended and may actually be 
unsafe, as it 1s a mutagen. Foods containing quercetin contain the 
mutagens as well as antimutagens that balance each other (19). 
Rutin, a flavone, is composed of two glycosides, hesperidin and 
eriodectyol. Rutin is water-soluble and is found in grains, specifically 
buckwheat (15). 
3. Flavonols The flavonols, also pale yellow pigments, 
have the only group of flavonoids that are a non-phenolic hydroxyl 
group attached at the C3 position. Flavonols are precursors of 
anthocyanins being enzymatically changed through illumination (18). 
Anthocyanins and catechols, are found throughout the fruit or 
vegetable, however, the anthoxanthins are reduced with peeling as it 
decreases in concentration towards the central core (5,18). The 
nutrition value of these bioflavonoids is not decreased or lost with 
cooking and processing except in extreme illumination (18). Limited 
research is available at this time on any of the synthetic or pill-form 
bioflavonoids. Foods containing any of the bioflavonoids would be 
the safest method to receive the beneficial results of the flavonoids 
at this time. 
Szent-Gyorgi conducted studies showing that flavonoids 
"decreased capillary fragility and permeability", therefore the 
flavonoids were named vitamin P for permeability in 1936. By 1950 
this name ·was dropped as there was nothing to support that 
flavonoids were "essential" for normal metabolism or development, 
which defines a vitamin (5). They are now known as the 
bioflavonoids not vitamin P, but some literature may still use the 
vitamin term. 
HOW BIOFLA VONOIDS PROTECT AGAINST FREE RADICAL DAMAGE 
Bioflavonoids have been shown to quench free radicals and 
thus can protect against oxidative modifications that are associated 
with atherosclerosis and coronary heart disease. They can also 
inhibit platelet aggregation which is associated with atherosclerosis. 
The following studies describe the association of bioflavonoids and 
coronary heart disease and atherosclerosis. 
Flavonoids appear to be involved in the "French paradox": 
decreased coronary atherosclerosis with a high fat dietary intake. 
Since high fat intake is associated with coronary heart disease, 
researchers wanted to know how the French people with a diet high 
in fats could have a low level of coronary atherosclerosis. Along with 
the high fat diet, the French people also consume a high level of red 
wine. The phenolic substances found in the red wine were tested for 
their effects on lipid peroxidation and were able to inhibit 60-98% 
lipid peroxidation depending on the concentration (20). The results 
of the study suggest that the phenolic flavonoid substances found in 
the red wine inhibited lipid peroxidation and thus the French have 
less atherosclerosis and coronary heart disease than their high fat 
diet would suggest. This shows how powerful the antioxidant effect 
of the bioflavonoids can be. 
The Seven Countries Study looked at 12,763 men aged 40-59 
years old and their lifestyles including flavonoid intake. After 25 
years, the individuals with the lowest flavonoid intake showed the 
highest coronary heart disease mortality and vise versa. The highest 
correlation with increased coronary heart disease mortality was a 
high intake of saturated fats, followed by smoking and low flavonoid 
intake (21 ). 
A similar study assessed 34,789 male health professionals over 
6 years. No significant correlation between flavonoid intake and 
coronary heart disease was found, although in men who had previous 
cardiovascular disease total flavonoid intake reduced their risk of 
death from the disease (22). 
The Zutphen Elderly Study, conducted in the eastern 
Netherlands, measured flavonoid intake of 939 men aged 65-84 and 
assessed the relationship of the flavonoid level to coronary heart 
disease and myocardial infarction incidence. They first determined 
the amount of flavonoids present in various fruits, vegetables, and 
beverages (teas and wines) by sampling from three different 
supermarkets in their area. Complete information was gathered on 
the subject's diet and risk factors. Over a five year span the 
flavonoid intake was significantly related to a decrease in mortality 
from coronary heart disease. An inverse relationship between 
flavonoid intake and the incidence of myocardial infarction was 
borderline (23). This study did have a smaller sample size but also 
was confined to a smaller radius, possibly giving better control of the 
amount of flavonoids actually consumed by the subjects. 
A Canadian study also investigated the presumed benefits of 
red wine in coronary heart disease. The subjects were healthy 
individuals, free of any non-steroidal anti-inflammatory agents or 
aspirin that may have affected the platelet activity for the previous 
two weeks. By measuring the platelet concentrations before and 
after the flavonoids found in red wine were added, it was found that 
quercetin inhibited platelet aggregation. Thus, red wine was found 
to be more beneficial than other alcoholic products because the 
bioflavonoids can inhibit platelet aggregation (24 ). 
Another study observed flavonol effects on rabbits and cats. 
The in vivo effects proved to be more powerful than the flavonol 
effects tested in vitro. Flavonols showed antiplatelet aggregation and 
antithrombic action through two different mechanisms: free radical 
scavenging effects and ability to bind to platelet membranes. The 
flavonols, quercetin and rutin, actually disaggregated a platelet 
thrombus. The disaggregation doubled in effectiveness when also 
being treated with a cyclo-oxygenase inhibitor such as aspirin (7). 
The free radical scavenging effects of the flavonols prevented 
damage to the endothelial secreting mechanism that produces EDRF. 
Like the current daily low dose aspirin therapy, the 
bioflavonoids have been shown to inhibit platelet aggregation and 
atherosclerosis. Since the phenolic compounds demonstrate 
inhibition of both lipid peroxidation and platelet aggregation, they 
may be more powerful than current therapies. 
In addition to epidemiological studies, the flavonoids have been 
tested in the laboratory for their effects of lipid oxidations. 
Quercetin was tested for inhibition of lipid peroxidation based on 
concentration. One micromole of quercetin gave around 25% 
inhibition. Ninety-five percent inhibition of lipid peroxidation was 
achieved with five to ten micromoles (25), thereby showing the 
favorable antioxidant activity of quercetin. When flavonoids were 
tested for protection of lipid peroxidation, quercetin, baicalein, and 
myricetin showed to have the strongest in antioxidant effects (26). 
To test for free radical reduction and inhibition of lipid 
peroxidation, flavonoids were added to an in vitro system where 
gamma-linolenic acid (GLA) stimulated lipid peroxidation m 
lymphoma cells. Quercetin, the most effective compound, at a 
concentration of 10-50 micromoles, lowered lipid peroxidation 
almost 50%, but when 100 micromoles were added to the system, 
there was the same reduction(50%) of lipid peroxidation. Thus, a 
very low concentration of quercetin shows the maximum protection. 
Rutin showed a 37% inhibition of GLA-induced lipid peroxidation. 
The same study also measured the effects of fat-soluble vitamins, 
retinol (vitamin A), retinoic acid, and alpha-tocopherol (vitamin E), 
on GLA-induced lipid peroxidation. The scavenging effect on free 
radicals was shown to be dose-dependent for the fat soluable 
vitamins with an overall reduction of lipid peroxidation significantly 
less than the flavonoids (27). Again bioflavonoid therapies may be 
more effective than therapy with vitamin E. 
Quercetin has also shown to block the synthesis of hepoxilins, 
normally produced through arachidonate metabolism. When these 
hepoxilins are produced they cause endothelial damage of the 
arterioles leading to arteriosclerosis (26). The flavone, quercetin, 
inhibits the production of the hepoxilins, therefore inhibiting 
arteriosclerosis. Other flavonoids may have similar effects but 
further testing IS needed. 
When flavonoids were measured for their scavenging 
effects, the most potent was catechin followed by epicatechin and 
rutin based on the flavonoid concentration needed to neutralize 50% 
of the hydroxyl free radicals in the "Fenton system" (28). 
When dealing with human subjects it is extremely difficult to 
keep all control factors equal and only measure one variable, such as 
flavonoid intake. Although the subjects are closely questioned about 
their nutrition and lifestyles, it is almost impossible for all subjects to 
eat the exact diet over a period of years. Based on the in vitro, as 
well as in vivo data, flavonoids help protect against atherosclerosis. 
Because the incidence of age-related macular degeneration increases 
with atherosclerosis, the flavonoid intake should reduce the 
incidence and severity of this eye disease. 
The lens of the eye is continuously producing layers throughout 
life and therefore is especially susceptible to free radical damage 
(15). Age-related cataracts have been shown to be caused by free 
radical damage and lipid peroxidation. In the previous studies 
discussed, bioflavonoids have scavenged free radicals to prevent free 
radical damage and inhibited lipid peroxidation. Further studies 
should be performed on the exact effects of a high intake of 
bioflavonoids on cataract development. 
CAROTENOIDS 
Carotenoids are a widely distributed family of tetraterpenes 
that are synthesized by a large variety of photo synthetic micro-
organisms and members of the plant kingdom (29). There are over 
563 carotenoids that have been identified, but only 50 have the 
ability to be enzymatically converted to retinol (vitamin A) in a 
variety of animals including humans. In nature, carotenoids exist m 
several forms including hydrocarbons (beta carotene and lycopene) 
and oxygenated derivatives (oxycarotenoids or xanthophyls). Some 
carotenoids, such as beta carotene, can and do serve as a large 
dietary portion of vitamin A in human nutrition (30). Relatively few 
details of the mechanisms and regulation of metabolism, distribution, 
tissue make up and tissue deposition of these compounds in humans 
is known (31). Absorption of both carotenes and xanthophyls is 
believed to be in a relatively non-specific fashion. The hydrocarbons 
are thought to be mainly metabolized to retinol in the mucosal cells 
of the intestinal tract. However, all of the carotenoids are also 
absorbed during intake. After absorption, the carotenoids are stored 
in several tissues and organs predominantly the liver and adipose 
tissue. Noted levels are also found in the adrenals and the testes. 
The transportation of carotenoids through the body is done by 
lipoproteins in the human plasma. Human plasma contains a 
complex mixture of structurally diverse carotenoids. Carotenoids 
that are found in substantial concentrations in human plasma are 
beta and alpha carotene, lutein, lycopene, and beta-cryptoxanthin 
(32). Research has shown that 75% of blood carotenoids are 
hydrocarbons, which bind with low density lipoproteins (LDL) in the 
human plasma. The remaining 25% of blood carotenoids attach to 
high density lipoproteins (HDL). Lutein, a xanthophylic carotenoid, 1s 
distributed equally between HDL and LDL in the human plasma (33). 
There are several determinants that influence serum carotenoid 
levels including dietary intake, destruction in the gastrointestinal 
tract, efficiency of absorption and metabolism, and rate of tissue 
uptake. There does not appear to be a definable level of toxicity 
associated with excessive carotenoid intake except for the deposition 
of yellow pigment in the skin (34 ). 
Carotenoids are found predominately in fruits and vegetables, 
with moderate amounts found in grains, fats, diary products, and 
eggs (35). Low amounts of carotenoids are found in fish and meats 
(36,37). Tomatoes are a major source of lycopene (hydrocarbon), 
which 1s the most abundant carotenoid found in the human serum 
(38). Spinach along with collard greens are good sources of lutein 
and zeaxanthin (xanthophylls). When comparing the lutein 
concentrations in broccoli, brussel sprouts and spinach, there are as 
much as five times the concentration of lutein as the concentration of 
beta carotene in those vegetables (table 1)(39). Lutein is the 
compound that makes corn yellow and gives marigolds their natural 
yellow color. 
HOW CAROTENOIDS PROTECT AGAINST FREE RADICAL DAMAGE 
Carotenoids have the ability to interact with various radical 
species to protect the organism and cells from adverse effects of 
light, air, and sensitizer pigments (39). The mechanism of how the 
GOODSOURCESOFCAROTENOIDS 
Vegetable Alpha- Beta-
Fruit Carotene Carotene Lycopene Lutein 
Broccoli 700 1,900 
Brussel Sprouts 480 1,300 
Cabbage 80 150 
Carrots 3600 7,900 260 
Corn 50 51 780 
Green Beans 630 44 740 
Kale 4,700 21,900 
Leaf Lettuce 1 1,200 1,800 
Peas (Green) 16 350 1,700 
Spinach 4,100 10,200 
Winter Squash 12 820 38 
Summer Squash 12 420 1,200 
Tomatoes 520 3,100 100 
Carotenoid content micrograms per 100 grams 
Mangels, A.R.; Holden, J.M.; Beecher, G.R.; Forman,M.R.; Lanza, E. 1 Am Diet 
Assoc. 1993;93:284-296. 
carotenoids quench the active oxygen species 1s still unclear. 
However, some results suggest the free radical's primary site of 
attack is the terminal 5,6-double bonds in the intact carotenoid 
molecule (39). 
Antioxidant properties exist in carotenoids other than beta 
carotene. For example, USDA researchers showed that lutein and 
lycopene are active antioxidants in human sera. In addition lutein 
has more biological antioxidant activity in the blood serum than any 
other carotenoid (40). Researchers in Germany have shown that 
lycopene and lutein are effective in quenching singlet oxygen. As an 
overall antioxidant, lutein appears to be a key component with the 
other antioxidants in the prevention of the deleterious effects of the 
oxidation process from free radicals (41). 
In the United States, ARMD is the leading cause of irreversible 
blindness in adults older than sixty-five years. Oxidative damage of 
the photoreceptors in the macula is one factor which is thought to 
cause the development of age-related macular degeneration. Past 
epidemiological studies have implied that decreased amounts of 
carotenoid intake leads to an increased incidence of late ARMD 
(31,42,43). During 1992 through 1994 three important ARMD 
studies were reported. The first article documented for the first time 
a connection between reduced incidence of ARMD and high levels of 
carotenoids in the blood ( 44 ). The second paper, separated the 
different carotenoids that were associated with the risk of ARMD. 
Lutein, for the first time, was found to be significantly correlated 
with a reduced risk of macular degeneration ( 45). The third paper 
by Seddon et al. defined the important role of carotenoids, 
specifically lutein and zeaxanthin in the reduction of ARMD. These 
researchers observed that adults m the highest quintile of carotenoid 
intake had a 43% lower risk of ARMD compared with adults in the 
lowest quintile. When they assessed intake of specific carotenoids, 
lutein and zeaxanthin were most strongly associated with a 
decreased risk of ARMD. The foods most associated with decreased 
risk were spinach and collard greens, both high in lutein and 
zeaxanthin (43). 
In a study by Landrum et al., lutein and zeaxanthin were found 
to exist in the macula. In a study published in 1997, Landrum et al. 
furthered their research by plotting out specific concentration 
differences between lutein and zeaxanthin within the macula. They 
found on average 70% of the total carotenoids found in controls, was 
zeaxanthin and this percent was consistent across the retina. 
Seventeen of twenty-two ARMD eyes had total amounts of lutein and 
zeaxanthin in central three millimeters of the retina which were 
below the mean for the control group. For the outer regions of the 
macula, eleven and twenty-one millimeters from the macula, 15 of 
ARMD group (68%) were found to be lower in total carotenoid 
content than the mean corresponding regions in the control group. 
The distributions of lutein and zeaxanthin were similar in both 
groups. Macular pigmentation increase appears to be a slow process 
as demonstrated by the rate of 13.9X10 absorbance units/week. 
This amounted to 15% increase in pigment level after 72 days of 
lutein supplementation. The results of this study revealed that slow, 
significant increases m the level of pigmentation were seen in those 
subjects with lutein supplementation over a long period of time (46). 
Since the carotenoids lutein and zeaxanthin comprise the 
macular pigment, they are our best defense against excited triplet 
states and singlet oxygen in the retina. They are believed to serve 
actively to protect the nerve tissue of the macula, acting as a shield 
to those tissues posterior to the outer plexiform layer from excessive 
blue light (47). Photoreceptors, Bruch's membrane, and the RPE are 
those structures that are most severely damaged m ARMD and are 
found posterior to the macular carotenoids (46). From the Sedden et 
al. study, it appears the daily intake of six milligrams of lutein can 
significantly lower an individuals risk of contracting ARMD (43). The 
decrease in macular pigmentation has been correlated with the onset 
of ARMD (46). 
Workers at the Hawaii Cancer Center showed that lutein is the 
most effective carotenoid to inhibit lipid peroxidation which is one 
oxidation process that occurs in the human serum and the eye (48). 
A study from the Department of Ophthalmology and Visual Sciences 
investigated relationships between levels of toxopherols (vitamin E) 
and carotenoids in the serum and ARMD. The results showed no 
significant difference between levels of carotenoids and vitamin E 
and ARMD when controlling levels of cholesterol in the sample. They 
did however discover that persons with decreased levels of lycopene 
m their serum had twice as likely a chance of having ARMD (42). 
Research has found that oxidative modification of lens proteins 
mediated· by light leads to insolubilization, and thus cataracts. There 
is some evidence showing the importance of lutein and zeaxanthin in 
reducing cataract formation. A recent report based on lenses from a 
seventy-two year old woman has revealed the presence of 
carotenoids in the human lens (49). In a study of fifty thousand 
women, researchers examined cataract formation over an eight year 
period. The consumption of spinach, which is an ideal source of 
lutein and zeaxanthin, lead to much lower levels of cataract 
formation than the consumption of any other vegetables, including 
carrots, sweet potatoes, and winter squash, which contain high 
amounts of beta carotene and little lutein (50). 
The role of lutein in reduction of cataract formation Is farther 
illustrated in a paper by Yeum et al. Researchers at Tuft University 
USDA Research Center in Boston. These researchers showed for the 
first time that lutein and zeaxanthin were found in the lens. They 
confirmed earlier work that no other carotenoids are found in the 
eye (51). The researchers at Tuft also reported the presence of 
lutein and zeaxanthin in the food groups of those nutrients that were 
earlier believed to reduce and/or prevent cataract formation. The 
results of a study by Jacques et al. supported the hypothesis that the 
lens' antioxidant defense may play a role in cataractogenesis 
particularly when the individual has high plasma levels of two or 
more of the following vitamins; vitamin C, vitamin E, and carotenoids. 
These vitamins appear to influence antioxidant status and reduce the 
risk of cataract formation (52). 
SUMMARY 
Increasing environmental oxidative stresses are causmg the 
need for more antioxidant protection for our bodies. The powerful 
antixoidative properties of bioflavonoids and carotenoids may play 
an important role in prevention of two major eye disorders, age-
related macular degeneration and cataracts, as well as other 
circulatory diseases. Current antioxidant therapies may be even 
more beneficial with the use of bioflavonoids and carotenoids. 
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